Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.82 |
| ▸ | ERBB2 | P04626 | 20/20 | 0.82 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.65 |
| ▸ | LCK | P06239 | 1/20 | 0.65 |
| ▸ | LYN | P07948 | 1/20 | 0.65 |
| ▸ | MET | P08581 | 1/20 | 0.65 |
| ▸ | SRC | P12931 | 1/20 | 0.65 |
| ▸ | CSK | P41240 | 1/20 | 0.65 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.65 |
| ▸ | TEK | Q02763 | 1/20 | 0.65 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3405235 | 0.96 | EGFR (0.77) | EGFRERBB2ERBB4LCKLYN | |
| SCHEMBL3403405 | 0.91 | EGFR (0.81) | EGFRERBB2ERBB4LCKLYN | |
| Hydrochloric Acid SCHEMBL3403689 | 0.91 | EGFR (0.69) | EGFRERBB2ERBB4LCKLYN | |
| SCHEMBL3400705 | 0.90 | EGFR (0.82) | EGFRERBB2ERBB4LCKLYN | |
| SCHEMBL13070990 | 0.90 | EGFR (0.82) | EGFRERBB2ERBB4LCKLYN | |
| SCHEMBL3403786 | 0.90 | EGFR (1.00) | EGFRERBB2ERBB4LCKLYN | |
| SCHEMBL3403796 | 0.90 | EGFR (0.85) | EGFRERBB2ERBB4LCKLYN | |
| SCHEMBL4288120 | 0.88 | EGFR (0.79) | EGFRERBB2ERBB4LCKLYN | |
| SCHEMBL3400698 | 0.88 | EGFR (0.85) | EGFRERBB2ERBB4LCKLYN | |
| SCHEMBL3404906 | 0.88 | EGFR (0.86) | EGFRERBB2ERBB4LCKLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253633-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
| EP-2253633-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
| US-20090233937-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233937-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233937-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233937-A1 | FUSED HETEROCYCLIC COMPOUND | ROS1, JAK2, ERBB2 | EGFR 11/4885ERBB2 3/4885ERBB4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.